Shiho Kanai Selected Research

3- (1- (4- phenoxyphenyl)- 3- (2- phenylethyl)- 1H- indol- 5- yl)propanoic acid

3/2016

ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shiho Kanai Research Topics

Disease

3	Inflammation (Inflammations) 03/2016 - 10/2012
2	Fatty Liver 03/2016 - 01/2011
2	Fibrosis (Cirrhosis) 03/2016 - 10/2012
1	Non-alcoholic Fatty Liver Disease 03/2016
1	Thrombosis (Thrombus) 11/2011
1	Hepatocellular Carcinoma (Hepatoma) 01/2011

Drug/Important Bio-Agent (IBA)

3	Group IV Phospholipases A2IBA 03/2016 - 10/2012
2	Carbon Tetrachloride (Tetrachloromethane)IBA 03/2016 - 10/2012
2	LipidsIBA 03/2016 - 10/2012
1	CholesterolIBA 03/2016
1	PropaneIBA 03/2016
1	PropionatesIBA 03/2016
1	SaltsIBA 03/2016
1	3- (1- (4- phenoxyphenyl)- 3- (2- phenylethyl)- 1H- indol- 5- yl)propanoic acidIBA 03/2016
1	EnzymesIBA 10/2012
1	Proteins (Proteins, Gene)FDA Link 10/2012
1	Arachidonic Acid (Vitamin F)IBA 10/2012
1	Plasminogen Activator Inhibitor 1IBA 11/2011
1	Linoleic Acid (Linoleate)IBA 01/2011
1	Oleic Acid (Oleate)IBA 01/2011
1	Triglycerides (Triacylglycerol)IBA 01/2011
1	Nonesterified Fatty Acids (NEFA)IBA 01/2011
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2011